Annual EBIT
-$35.47 M
+$24.86 M+41.21%
December 31, 2023
Summary
- As of February 7, 2025, ALDX annual earnings before interest & taxes is -$35.47 million, with the most recent change of +$24.86 million (+41.21%) on December 31, 2023.
- During the last 3 years, ALDX annual EBIT has risen by +$657.70 thousand (+1.82%).
- ALDX annual EBIT is now -368.32% below its all-time high of $13.22 million, reached on December 31, 2013.
Performance
ALDX EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$14.63 M
+$1.74 M+10.61%
September 30, 2024
Summary
- As of February 7, 2025, ALDX quarterly earnings before interest & taxes is -$14.63 million, with the most recent change of +$1.74 million (+10.61%) on September 30, 2024.
- Over the past year, ALDX quarterly EBIT has dropped by -$6.99 million (-91.34%).
- ALDX quarterly EBIT is now -255.52% below its all-time high of $9.41 million, reached on December 31, 2013.
Performance
ALDX Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$42.83 M
-$6.99 M-19.49%
September 30, 2024
Summary
- As of February 7, 2025, ALDX TTM earnings before interest & taxes is -$42.83 million, with the most recent change of -$6.99 million (-19.49%) on September 30, 2024.
- Over the past year, ALDX TTM EBIT has increased by +$847.70 thousand (+1.94%).
- ALDX TTM EBIT is now -335.71% below its all-time high of $18.17 million, reached on June 30, 2014.
Performance
ALDX TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
ALDX EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +41.2% | -91.3% | +1.9% |
| 3 y3 years | +1.8% | +4.9% | +17.6% |
| 5 y5 years | +8.4% | +21.7% | +30.4% |
ALDX EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +41.2% | -245.2% | +15.8% | -53.3% | +33.6% |
| 5 y | 5-year | at high | +42.4% | -245.2% | +15.8% | -53.3% | +33.6% |
| alltime | all time | -368.3% | +42.4% | -255.5% | +32.7% | -335.7% | +33.6% |
Aldeyra Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$14.63 M(-10.6%) | -$42.83 M(+19.5%) |
| Jun 2024 | - | -$16.37 M(+115.9%) | -$35.84 M(+28.3%) |
| Mar 2024 | - | -$7.58 M(+78.9%) | -$27.93 M(-21.3%) |
| Dec 2023 | -$35.47 M(-41.2%) | -$4.24 M(-44.6%) | -$35.47 M(-18.8%) |
| Sep 2023 | - | -$7.65 M(-9.6%) | -$43.67 M(-12.9%) |
| Jun 2023 | - | -$8.46 M(-44.1%) | -$50.16 M(-15.1%) |
| Mar 2023 | - | -$15.12 M(+21.6%) | -$59.07 M(-2.1%) |
| Dec 2022 | -$60.33 M(+7.7%) | -$12.44 M(-12.0%) | -$60.33 M(-4.6%) |
| Sep 2022 | - | -$14.14 M(-18.6%) | -$63.23 M(-1.9%) |
| Jun 2022 | - | -$17.37 M(+6.0%) | -$64.48 M(+4.7%) |
| Mar 2022 | - | -$16.38 M(+6.8%) | -$61.61 M(+9.9%) |
| Dec 2021 | -$56.03 M(+55.1%) | -$15.34 M(-0.3%) | -$56.03 M(+7.8%) |
| Sep 2021 | - | -$15.38 M(+6.1%) | -$51.97 M(+15.6%) |
| Jun 2021 | - | -$14.50 M(+34.2%) | -$44.98 M(+19.9%) |
| Mar 2021 | - | -$10.81 M(-4.2%) | -$37.51 M(+3.8%) |
| Dec 2020 | -$36.13 M(-41.3%) | -$11.28 M(+34.6%) | -$36.13 M(-3.6%) |
| Sep 2020 | - | -$8.38 M(+19.2%) | -$37.46 M(-21.6%) |
| Jun 2020 | - | -$7.03 M(-25.4%) | -$47.76 M(-11.6%) |
| Mar 2020 | - | -$9.43 M(-25.3%) | -$54.03 M(-12.2%) |
| Dec 2019 | -$61.53 M(+58.8%) | -$12.62 M(-32.5%) | -$61.53 M(+3.4%) |
| Sep 2019 | - | -$18.69 M(+40.5%) | -$59.49 M(+15.3%) |
| Jun 2019 | - | -$13.30 M(-21.5%) | -$51.58 M(+9.0%) |
| Mar 2019 | - | -$16.93 M(+60.2%) | -$47.31 M(+22.1%) |
| Dec 2018 | -$38.75 M | -$10.57 M(-2.0%) | -$38.75 M(+10.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | -$10.78 M(+19.5%) | -$35.10 M(+19.9%) |
| Jun 2018 | - | -$9.02 M(+7.8%) | -$29.27 M(+14.7%) |
| Mar 2018 | - | -$8.37 M(+20.9%) | -$25.53 M(+14.9%) |
| Dec 2017 | -$22.23 M(+19.5%) | -$6.92 M(+39.6%) | -$22.23 M(+11.5%) |
| Sep 2017 | - | -$4.96 M(-6.1%) | -$19.93 M(+1.1%) |
| Jun 2017 | - | -$5.28 M(+4.3%) | -$19.72 M(+5.4%) |
| Mar 2017 | - | -$5.06 M(+9.5%) | -$18.71 M(+0.7%) |
| Dec 2016 | -$18.59 M(+55.2%) | -$4.63 M(-2.6%) | -$18.59 M(+1.6%) |
| Sep 2016 | - | -$4.75 M(+11.1%) | -$18.29 M(+8.4%) |
| Jun 2016 | - | -$4.27 M(-13.5%) | -$16.88 M(+14.0%) |
| Mar 2016 | - | -$4.94 M(+14.2%) | -$14.81 M(+23.7%) |
| Dec 2015 | -$11.98 M(+142.3%) | -$4.33 M(+29.7%) | -$11.98 M(+19.1%) |
| Sep 2015 | - | -$3.34 M(+51.4%) | -$10.06 M(+15.8%) |
| Jun 2015 | - | -$2.20 M(+4.5%) | -$8.69 M(+14.9%) |
| Mar 2015 | - | -$2.11 M(-12.5%) | -$7.57 M(+53.1%) |
| Dec 2014 | -$4.94 M(-137.4%) | -$2.41 M(+22.5%) | -$4.94 M(-171.9%) |
| Sep 2014 | - | -$1.97 M(+82.4%) | $6.88 M(-62.1%) |
| Jun 2014 | - | -$1.08 M(-309.5%) | $18.17 M(+2.7%) |
| Mar 2014 | - | $515.00 K(-94.5%) | $17.69 M(+33.8%) |
| Dec 2013 | $13.22 M(-158.2%) | $9.41 M(+0.9%) | $13.22 M(-173.8%) |
| Sep 2013 | - | $9.32 M(-700.2%) | -$17.92 M(-34.2%) |
| Jun 2013 | - | -$1.55 M(-60.8%) | -$27.24 M(+6.0%) |
| Mar 2013 | - | -$3.96 M(-81.8%) | -$25.69 M(+18.2%) |
| Dec 2012 | -$22.73 M(+983.5%) | -$21.73 M | -$21.73 M |
| Dec 2011 | -$2.10 M | - | - |
FAQ
- What is Aldeyra Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Aldeyra Therapeutics?
- What is Aldeyra Therapeutics annual EBIT year-on-year change?
- What is Aldeyra Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Aldeyra Therapeutics?
- What is Aldeyra Therapeutics quarterly EBIT year-on-year change?
- What is Aldeyra Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Aldeyra Therapeutics?
- What is Aldeyra Therapeutics TTM EBIT year-on-year change?
What is Aldeyra Therapeutics annual earnings before interest & taxes?
The current annual EBIT of ALDX is -$35.47 M
What is the all time high annual EBIT for Aldeyra Therapeutics?
Aldeyra Therapeutics all-time high annual earnings before interest & taxes is $13.22 M
What is Aldeyra Therapeutics annual EBIT year-on-year change?
Over the past year, ALDX annual earnings before interest & taxes has changed by +$24.86 M (+41.21%)
What is Aldeyra Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of ALDX is -$14.63 M
What is the all time high quarterly EBIT for Aldeyra Therapeutics?
Aldeyra Therapeutics all-time high quarterly earnings before interest & taxes is $9.41 M
What is Aldeyra Therapeutics quarterly EBIT year-on-year change?
Over the past year, ALDX quarterly earnings before interest & taxes has changed by -$6.99 M (-91.34%)
What is Aldeyra Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of ALDX is -$42.83 M
What is the all time high TTM EBIT for Aldeyra Therapeutics?
Aldeyra Therapeutics all-time high TTM earnings before interest & taxes is $18.17 M
What is Aldeyra Therapeutics TTM EBIT year-on-year change?
Over the past year, ALDX TTM earnings before interest & taxes has changed by +$847.70 K (+1.94%)